Wave Life Sciences reports WVE-006 achieves MZ-like phenotype
WVE-006 showed 64% wild-type M-AAT, 71% reduction in Z-AAT, and sustained editing up to three months post-dose.
See the latest news and media coverage for Wave Life Sciences. We track all announcements, press releases, and industry mentions in real time, all in one place.
RNA medicines developer
wavelifesciences.comLast updated
In short: Wave Life Sciences advanced its obesity and AATD programs while reporting strong Q1 2026 financial results and plans to redomicile to the US.
WVE-006 showed 64% wild-type M-AAT, 71% reduction in Z-AAT, and sustained editing up to three months post-dose.
Cash stands at $544.6 million with runway into 3Q 2028. Pipeline updates include INLIGHT Phase 2a initiation in 2Q 2026 and RestorAATion-2 data in May 2026.
They invite registration for the webcast.
The Singapore High Court will hear the application on April 29, 2026, and related filings will be available on the investor relations website.
Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2...
Results from multiple Phase 2b dose finding studies for berobenatide (PF’3944) highlight a potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, and support the...
On May 15, 2026, Exome Asset Management reported selling out of Wave Life Sciences (NASDAQ:WVE),...
Earlier this month, Wave Life Sciences reported updated RestorAATion-2 data showing its RNA-editing candidate WVE-006 reduced harmful Z-AAT and restored protective M-AAT to MZ-like levels...
Track Wave Life Sciences and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Wave Life Sciences and other trending companies.